---
title: "Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294684860.md"
description: "A Phase 2 clinical trial proposal has been submitted, outlining plans for a small-scale study aimed at facilitating regulatory discussions and potential approval in the event of favorable outcomes. The study is intended to involve a limited number of participants and is crucial for advancing the research in question."
datetime: "2026-08-03T11:03:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294684860.md)
  - [en](https://longbridge.com/en/news/294684860.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294684860.md)
---

# Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome

A Phase 2 clinical trial proposal has been submitted, outlining plans for a small-scale study aimed at facilitating regulatory discussions and potential approval in the event of favorable outcomes. The study is intended to involve a limited number of participants and is crucial for advancing the research in question.

### Related Stocks

- [CANF.US](https://longbridge.com/en/quote/CANF.US.md)

## Related News & Research

- [Can-Fite plans Phase IIb trial of namodenoson plus gemcitabine in advanced pancreatic cancer](https://longbridge.com/en/news/296095129.md)
- [Can-Fite says Phase III namodenoson trial in advanced liver cancer advances under FDA, EMA guidance](https://longbridge.com/en/news/295654944.md)
- [Here's How Much $1000 Invested In Lowe's Companies 15 Years Ago Would Be Worth Today](https://longbridge.com/en/news/296254984.md)
- [Lowe's Q2 Comps Were Better Than Feared, Guidance Reflects H2 Below Expectations](https://longbridge.com/en/news/296375209.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)